Galera Therapeutics
Pennsylvania, United States · Healthcare, Health Care
Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
Key facts
- Headquarters
- Pennsylvania, United States
- Employees
- 14
- Industries
- Healthcare, Health Care
- Website
- galeratx.com
- Company page
Recent activity at Galera Therapeutics
- : SEC 8-K (5.02): In connection with the Galera Merger, effective August 3, 2026, multiple directors including J. Mel. Sorensen, Michael Friedman, Nancy Chang, Lawrence Alleva, and Kevin Lokay resigned from the Board of the Company, which has now become a wholly owned subsidiary of Obsidian Therapeutics, Inc. These resignations were not due to any disagreements with the Company. Concurrently, new officers including Madan Jagasia, Julie Feder, Parameswaran Hari, and Dana Alexander were appointed to lead the Company post-merger. This restructuring reflects significant governance changes as a result of the merger agreement.
- : SEC 8-K (7.01): This filing reports a Regulation FD Disclosure regarding the anticipated closing of mergers involving Galera Therapeutics, Inc. scheduled for August 3, 2026, contingent upon customary closing conditions. A Pre-Closing Distribution has been declared that allows holders of Galera’s common stock to receive contingent value rights (CVRs). Each CVR grants rights to potential cash payments from the commercialization of specific products containing tilarganine, GC4711 (rucosopasem), and GC4419 (avasopasem). The record date for the distribution is set for July 31, 2026, while the actual distribution is expected on August 6, 2026, marking significant developments ahead of the merger completion.
- : SEC 8-K (8.01): On July 7, 2026, Galera Therapeutics, Inc. announced a one-for-two hundred (1:200) Reverse Stock Split of its common stock approved by its board of directors. This significant corporate action is set to take effect on July 12, 2026, at 11:59 p.m. Eastern Time, with trading on a split-adjusted basis commencing on July 13, 2026. The Reverse Stock Split will convert every two hundred shares of common stock into one share, impacting the number of shares available for issuance under the Company's equity plans and stock options. Notably, there will be proportional adjustments in exercise prices for outstanding stock options and warrants, aimed at maintaining the economic equivalence of equity interests post-split. This strategic move is intended to enhance the marketability of the Company's stock.
- : SEC 8-K (8.01):
- : SEC 8-K (5.03): On May 11, 2026, Galera Therapeutics, Inc. filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of Delaware, increasing the number of authorized shares of common stock from 200 million to 400 million. Additionally, on May 12, 2026, the company provided its stockholders a right to act by written consent through another amendment. Both amendments were approved at the Annual Meeting of Stockholders held on May 8, 2026, indicating a significant change in corporate structure that enhances capital flexibility and shareholder rights. The strategic implications suggest a proactive approach to business expansion and shareholder engagement.
- : Galera Therapeutics and Obsidian merge to innovate
- : SEC 8-K (5.01): On April 14, 2026, Galera and Obsidian announced a significant change in control through the execution of a Merger Agreement and Securities Purchase Agreement. This transaction involves the merger of Galera with Obsidian, creating a newly-formed company that will be highlighted in future SEC filings, including a Form S-4 registration statement. The announcement was made via a press release and accompanied by an investor presentation, which are both included as exhibits in the filing. This merger is expected to have considerable implications for the strategic direction and governance structure of Galera, requiring careful examination by stockholders.
- : SEC 8-K (8.01): On April 7, 2026, Galera Therapeutics, Inc. executed a conversion of 76,479.175 shares of its Series B Non-Voting Convertible Preferred Stock into 76,479,164 shares of common stock, reflecting a significant shift in equity structure. This conversion was conducted in accordance with the Certificate of Designation related to the Series B Preferred Stock. Additionally, on April 8, 2026, affiliates of Ikarian Capital, LLC exercised warrants to purchase 8,488,229 shares of common stock, paying an aggregate exercise price of approximately $8,488.23. Following these transactions, a remaining balance of 42,839.11 shares of Series B Preferred Stock and 14,552,811 pre-funded warrants to purchase common stock are still outstanding, indicating ongoing investment activity and future capital potential for the company.
- : SEC 8-K (8.01):
- : SEC 8-K (5.02):
Galera Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2025 | Seed | $2.9M |
| Jan 2025 | Seed | $2.7M |
| Nov 2016 | Venture | $15.0M |
| Oct 2015 | Venture | $37.1M |
Leadership
- Sorensen Mel, President & CEO
- Frank Torti, Director
- Henry Skinner, Director
- Campbell Murray, Director
- James Barrett, Director
- Thomas Dyrberg, Director
- Robert Beardsley, Executive Officer, Director
- J. Sorensen, Executive Officer, Director
- Eileen Romich, Administrative Assistant
Verified email and direct lines for Galera Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Galera Therapeutics files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Galera Therapeutics in the news
- Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - Yahoo Finance (Apr 14, 2026)
- Galera Therapeutics Announces Acquisition of Dismutase - GlobeNewswire (Oct 22, 2025)
- Galera Therapeutics Inc. (GRTX) Share Price Today | Galera Therapeutics (GRTX) Live NSE/BSE - Value Research (May 31, 2022)
Companies similar to Galera Therapeutics
- Actuate Therapeutics · Healthcare, Health Care
- Curadel Surgical Innovations · Healthcare, Health Care
- Akadeum Life Sciences · Healthcare, Health Care
- Resbiotic · Healthcare, Health Care
- Kernal Biologics · Healthcare, Health Care
About Galera Therapeutics: questions and answers
What does Galera Therapeutics do?
Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
Where is Galera Therapeutics headquartered?
Galera Therapeutics is headquartered in Pennsylvania, United States.
How many employees does Galera Therapeutics have?
Galera Therapeutics has about 14 employees.
Has Galera Therapeutics raised funding?
Yes. Fundz has recorded 4 funding events for Galera Therapeutics. The most recent, Seed of $2.9M, was in Jan 2025.
Who leads Galera Therapeutics?
Sorensen Mel is a President & CEO at Galera Therapeutics.
What is the latest news on Galera Therapeutics?
On Aug 04, 2026, SEC 8-K (5.02): In connection with the Galera Merger, effective August 3, 2026, multiple directors including J. Mel. Sorensen, Michael Friedman, Nancy Chang, Lawrence Alleva, and Kevin Lokay resigned from the Board of the Company, which has now become a wholly owned subsidiary of Obsidian Therapeuti
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy